Fay Y. Lin

2 weeks ago | genengnews.com | Fay Y. Lin

Home Topics Artificial Intelligence Million Species Listing: Basecamp Research Unearths Trove of Sequence Data From Novel... Basecamp Research collecting samples in Costa Rica [Coldhouse Collective] In the latest step to tackle biology’s data scaling law, Basecamp Research has announced BaseData, the largest database for sequence-based model training, composed of 9.8 billion new protein sequences and one million newly discovered species.

2 weeks ago | genengnews.com | Fay Y. Lin

Credit: nrqemi/iStock/Getty Images Plus In a study published in Nature Communications titled “Construction of multi-targeted CRISPR libraries in tomato to overcome functional redundancy at genome-scale level,” researchers from Tel Aviv University have developed a genetic editing method tailored to crop plants to influence various traits in tomato plants, including the taste and shape of the fruit.

2 weeks ago | genengnews.com | Fay Y. Lin

Credit: Tumeggy / Science Photo Library / Getty Images Lipid nanoparticle (LNP) mRNA vaccines induce robust immune responses and provide protection against infectious diseases. However, this immunity can be short-lived, resulting in the need for frequent booster vaccinations.

3 weeks ago | genengnews.com | Alex Philippidis |Fay Y. Lin |Uduak Grace Thomas |Corinna Singleman

A gene therapy clinical trial for Danon disease run by Rocket Pharmaceuticals has been suspended following the death of a patient. MIT and Recursion have released Boltz-2, an open-source tool that predicts molecular binding affinity at newfound speed and accuracy, aiming to democratize commercial drug discovery. Intellia Therapeutics saw its stock nosedive late last week after a patient in its Phase III trial of the CRISPR-based therapy experienced non-lethal liver toxicity.

3 weeks ago | genengnews.com | Fay Y. Lin

Researchers from the Massachusetts Institute of Technology (MIT) Jameel Clinic for Machine Learning in Health have announced the open-source release of Boltz-2, which now predicts molecular binding affinity at newfound speed and accuracy to democratize commercial drug discovery. The model is available under the highly permissive MIT license, which allows commercial drug developers to use the model internally and apply their own proprietary data.